Skip to main content
Top
Published in: Journal of General Internal Medicine 2/2010

01-02-2010 | Perspectives

Prevention of Type 2 Diabetes: Risk Status, Clinic, and Community

Authors: K. M. Venkat Narayan, MD, David F. Williamson, PhD

Published in: Journal of General Internal Medicine | Issue 2/2010

Login to get access

Abstract

Although the idea of preventing type 2 diabetes has been articulated since the discovery of insulin, only in the past decade have clinical trials demonstrated that diabetes can be prevented or delayed. These trials found lifestyle intervention reduces diabetes incidence by over 50% and is more efficacious than metformin. Evidence from prevention trials comes from persons with “pre-diabetes” in which blood glucose levels are elevated but not yet in the diabetes range. In normoglycemic persons, lifestyle or drug intervention has little impact on diabetes incidence. Prevention programs are often conducted outside the clinical sector where participants’ glycemic status is usually unknown; these programs may include many normoglycemic participants, which greatly reduces cost-effectiveness. An economically sustainable system for diabetes prevention will require effective partnerships among the clinical sector, community-based lifestyle programs, and third-party payers to ensure that limited resources for diabetes prevention are focused on persons at high risk of diabetes.
Literature
1.
go back to reference Joslin EP. The prevention of diabetes mellitus. JAMA. 1921;76:79–84. Joslin EP. The prevention of diabetes mellitus. JAMA. 1921;76:79–84.
2.
go back to reference Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Ämalainen H, Lanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.CrossRefPubMed Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Ämalainen H, Lanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.CrossRefPubMed
3.
go back to reference Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med. 2002;346:393–403.CrossRefPubMed Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med. 2002;346:393–403.CrossRefPubMed
4.
go back to reference Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, et al. TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program. New Engl J Med. 2006;355:241–50.CrossRefPubMed Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, et al. TCF7L2 polymorphisms and progression to diabetes in the diabetes prevention program. New Engl J Med. 2006;355:241–50.CrossRefPubMed
5.
go back to reference Moore AF, Jablonski KA, Mason CC, McAteer JB, Arakaki RF, Goldstein BJ, et al. The Association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program. J Clin Endocrinol Metab. 2008 Nov 18. [Epub ahead of print] Moore AF, Jablonski KA, Mason CC, McAteer JB, Arakaki RF, Goldstein BJ, et al. The Association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program. J Clin Endocrinol Metab. 2008 Nov 18. [Epub ahead of print]
6.
go back to reference The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28:888–94.CrossRef The Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28:888–94.CrossRef
7.
go back to reference Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, et al. The prevention of type 2 diabetes. Nature Clinical Practice Endocrinology & Metabolism. 2008;4:382–93.CrossRef Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, et al. The prevention of type 2 diabetes. Nature Clinical Practice Endocrinology & Metabolism. 2008;4:382–93.CrossRef
8.
go back to reference American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases. Prevention or delay of type 2 diabetes. Diabetes Care. 2004;27(Suppl 1):S47–54. American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases. Prevention or delay of type 2 diabetes. Diabetes Care. 2004;27(Suppl 1):S47–54.
10.
go back to reference Amundson HA, Butcher MK, Gohdes D, Hall TO, et al. Translating the diabetes prevention program into practice in the general community: findings from the montana cardiovascular disease and diabetes prevention programs. Diabetes Educ. 2009;35:209. doi:10.1177/0145721709333269.CrossRefPubMed Amundson HA, Butcher MK, Gohdes D, Hall TO, et al. Translating the diabetes prevention program into practice in the general community: findings from the montana cardiovascular disease and diabetes prevention programs. Diabetes Educ. 2009;35:209. doi:10.​1177/​0145721709333269​.CrossRefPubMed
12.
go back to reference American Diabetes Association. Screening for type 2 diabetes. Diabetes Care. 2004;27(Suppl. 1):S11–4. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care. 2004;27(Suppl. 1):S11–4.
13.
go back to reference World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications: Report of a WHO consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999 (WHO/NCD/NCS/99.2). World Health Organization: Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications: Report of a WHO consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999 (WHO/NCD/NCS/99.2).
14.
go back to reference Guangwei Li, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783–89.CrossRef Guangwei Li, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783–89.CrossRef
15.
go back to reference Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673–79.CrossRefPubMed Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673–79.CrossRefPubMed
16.
go back to reference Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med. 2008;121:519–24.CrossRefPubMed Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med. 2008;121:519–24.CrossRefPubMed
17.
go back to reference de Vegt F, Dekker JM, Jager A, Hienkens E, Stehouwer CDA, Nijpels G, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA. 2001;285:2109–13.CrossRefPubMed de Vegt F, Dekker JM, Jager A, Hienkens E, Stehouwer CDA, Nijpels G, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA. 2001;285:2109–13.CrossRefPubMed
18.
go back to reference Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose. Evidence Report/Technology Assessment No. 128. (Prepared by McMaster University Evidence-based Practice Center under Contract No. 290–02–0020). AHRQ Pub. No 05-E026–2. Rockville, MD: Agency for Healthcare Research and Quality. September 2005. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, et al. Diagnosis, Prognosis, and Treatment of Impaired Glucose Tolerance and Impaired Fasting Glucose. Evidence Report/Technology Assessment No. 128. (Prepared by McMaster University Evidence-based Practice Center under Contract No. 290–02–0020). AHRQ Pub. No 05-E026–2. Rockville, MD: Agency for Healthcare Research and Quality. September 2005.
19.
go back to reference Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Hold DD, Chaoyang LI, et al. Full accounting of diabetes and prediabetes in the US population, 1988–1994 and 2005–2006. Diabetes Care. 2009;32:287–94.CrossRefPubMed Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Hold DD, Chaoyang LI, et al. Full accounting of diabetes and prediabetes in the US population, 1988–1994 and 2005–2006. Diabetes Care. 2009;32:287–94.CrossRefPubMed
20.
go back to reference Smith GD, Bracha Y, Svendsen KH, Neaton JD, Haffner SM, Kuller LH. Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med. 2005;142:313–22. Smith GD, Bracha Y, Svendsen KH, Neaton JD, Haffner SM, Kuller LH. Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med. 2005;142:313–22.
21.
go back to reference Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27:155–61.CrossRefPubMed Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27:155–61.CrossRefPubMed
22.
go back to reference Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, et al. Effect of Orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care. 2007;30:27–32.CrossRefPubMed Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, et al. Effect of Orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care. 2007;30:27–32.CrossRefPubMed
23.
go back to reference Seidel MC, Powell RO, Zgibor JC, Siminerio LM, Platt GA. Translating the diabetes prevention program into an urban medically underserved community. Diabetes Care. 2008;31:684–9.CrossRefPubMed Seidel MC, Powell RO, Zgibor JC, Siminerio LM, Platt GA. Translating the diabetes prevention program into an urban medically underserved community. Diabetes Care. 2008;31:684–9.CrossRefPubMed
24.
25.
go back to reference Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med. 2008;358:661–3.CrossRefPubMed Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med. 2008;358:661–3.CrossRefPubMed
26.
go back to reference Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323–32.PubMed Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323–32.PubMed
27.
go back to reference Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251–64.PubMed Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251–64.PubMed
28.
go back to reference Ealovega MW, Tabaei BP, Brandle M, Burke R, Herman WH. Opportunistic screening for diabetes in routine clinical practice. Diab Care. 2004;27:9–12.CrossRef Ealovega MW, Tabaei BP, Brandle M, Burke R, Herman WH. Opportunistic screening for diabetes in routine clinical practice. Diab Care. 2004;27:9–12.CrossRef
29.
go back to reference Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the diabetes prevention program into the community: the DEPLOY pilot study. Am J Prev Med. 2008;35(4):357–63.CrossRefPubMed Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the diabetes prevention program into the community: the DEPLOY pilot study. Am J Prev Med. 2008;35(4):357–63.CrossRefPubMed
30.
go back to reference Heikes KE, Eddy DM, Arondekar B, Schlessinger L. Diabetes risk calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes. Diabetes Care. 2008;31:1040–5.CrossRefPubMed Heikes KE, Eddy DM, Arondekar B, Schlessinger L. Diabetes risk calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes. Diabetes Care. 2008;31:1040–5.CrossRefPubMed
32.
go back to reference Faith MS, Fontaine KR, Baskin ML, Allison DB. Toward the reduction of population obesity: macrolevel environmental approaches to the problems of food, eating, and obesity. Psychol Bull. 2007;33:205–26.CrossRef Faith MS, Fontaine KR, Baskin ML, Allison DB. Toward the reduction of population obesity: macrolevel environmental approaches to the problems of food, eating, and obesity. Psychol Bull. 2007;33:205–26.CrossRef
33.
go back to reference Rahman M, Simmons RK, Harding AH, Wareham NJ, Griffin SJ. A simple risk score identifies individuals at high risk of developing type 2 diabetes: a prospective cohort study. Fam Pract. 2008;25:191–6.CrossRefPubMed Rahman M, Simmons RK, Harding AH, Wareham NJ, Griffin SJ. A simple risk score identifies individuals at high risk of developing type 2 diabetes: a prospective cohort study. Fam Pract. 2008;25:191–6.CrossRefPubMed
34.
go back to reference Kahn HS, Cheng YJ, Thompson TJ, Imperatore G, Gregg EW. Two risk-scoring systems for predicting incident diabetes mellitus in US adults age 45 to 64 years. Ann Intern Med. 2009;150:741–51.PubMed Kahn HS, Cheng YJ, Thompson TJ, Imperatore G, Gregg EW. Two risk-scoring systems for predicting incident diabetes mellitus in US adults age 45 to 64 years. Ann Intern Med. 2009;150:741–51.PubMed
35.
go back to reference The International Expert Committee. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–44.CrossRef The International Expert Committee. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–44.CrossRef
39.
go back to reference Ackermann RT, Marrero DG. Adapting the diabetes prevention program lifestyle intervention for delivery in the community: the YMCA model. Diabetes Educ. 2007;33:69–78.CrossRefPubMed Ackermann RT, Marrero DG. Adapting the diabetes prevention program lifestyle intervention for delivery in the community: the YMCA model. Diabetes Educ. 2007;33:69–78.CrossRefPubMed
Metadata
Title
Prevention of Type 2 Diabetes: Risk Status, Clinic, and Community
Authors
K. M. Venkat Narayan, MD
David F. Williamson, PhD
Publication date
01-02-2010
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 2/2010
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-009-1148-9

Other articles of this Issue 2/2010

Journal of General Internal Medicine 2/2010 Go to the issue

Case Reports/Clinical Vignettes

Bat-Associated Leptospirosis

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.